NCT01243567

Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk for progression.

Conditions

• Glaucoma, Open-Angle

Interventions

Type	Name	Description
DRUG	bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution	Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
DRUG	latanoprost 0.005% ophthalmic solution	Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.

Timeline

• Start date: 2010-06-01
• Primary completion: 2012-02-14
• Completion: 2012-02-14
• First posted: 2010-11-18
• Last updated: 2019-04-18
• Results posted: 2013-02-26

Locations

2 sites across 2 countries: Portugal, Spain